20/05/2025
Exciting research update
** New research shows anti-CD3 antibody therapy could be a game-changer for type 1 diabetes **
A meta-analysis of 11 found that anti-CD3 monoclonal antibodies help preserve pancreatic function (C-peptide levels) and reduce daily needs in people with . 💪 Anti-CD3 monoclonal antibodies act by stopping the immune system from attacking the cells in the that produce insulin, potentially helping people with keep making insulin.
Who benefits most?
✅ Young people(≤18 years)
✅ Treatment started early (within 6 weeks of diagnosis)
✅ Higher doses (≥25 mg)
📌 The biggest predictor of success? The amount of the anti-CD3 antibody treatment given. Higher doses of the treatment seem more likely to help preserve insulin production and improve outcomes for people with type 1 diabetes. So, the more treatment received (within the recommended range), the better the chances of success.
With mostly mild, manageable side effects, this approach could reshape early T1D care. Early, high-dose intervention may give the best shot at preserving insulin production.
The study by Wu, Q., Wei, R., Liao, X. et al. was published this year in Cardiovascular Diabetology, and titled: "Anti-CD3 monoclonal antibody in treating patients with type 1 diabetes: an updated systematic review and meta-analysis". Access it online at https://doi.org/10.1186/s12933-025-02696-7